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of said complications is increasing
may be true, but this again had nothing
to do with the integrity of previous es-
timates made in a good faith effort to
study results. I hope this clarifies any
question in the readers’ minds as to
the intention of my statements regard-
ing this issue.
Daniel J. DiBardino, MD
Chief Resident in Cardiac Surgery
Brigham and Woman’s Hospital and
Children’s Hospital Boston Program
Boston, Mass
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PULMONARYARTERIAL
HYPERTENSION AND
CONGENITAL HEART
DISEASE: TARGETED
THERAPIES AND
OPERABILITY
To the Editor:
We read with great interest the case
report of Hoetzenecker and colleagues1
of a patient with severe pulmonary arte-
rial hypertension associated with an
atrial septal defect and the beneficial
effect of bosentan, which allowed for
closure of the defect. This is a very inter-
esting topic that raises a lot of cont-
roversies in the field of pulmonary
arterial hypertension associated with
congenital heart disease.2
I would like to comment on the he-
modynamic data presented in Table 1.
Total pulmonary resistance at baseline
is calculated at 460 dynes $ s1 $ cm5,
but pulmonary vascular resistance,
taking the mean left atrial pressure in
the calculation, which is commonly
done in congenital heart disease,
would give a value of 311 dynes $
s1 $ cm5 or 3.9 Wood units, which
is very close to a value of 3 Wood units
considered as totally safe for surgical
repair. If we calculate the ratio of pul-
monary to systemic blood flow (Qp/
Qs), we have a value of 2.7, which is
also considered a value that allows
for repair.
Moreover, when we look at the data
during the nitric oxide testing, these
values reach a pulmonary vascular resis-
tance of 1.78 Wood units or 142 dynes $
s1 $ cm5, the Qp/Qs is 3.25, and the
pulmonary arterial saturation reaches
84.5%. All these values are consistent
with a reactive pulmonary vascular
bed and are values that will clearly al-
low closure of the shunt for a congenital
cardiologist.3,4 It would be of interest
also to report the ratio of pulmonary
over systemic vascular resistance, as
a ratio<0.33 indicates good prognosis
after closure of the shunt.4
Maybe the authors used the defini-
tion of reactivity used for other forms
of pulmonary arterial hypertension, al-
lowing for the use of calcium channel
blockers, but this may not be applied
for the evaluation of operability in pa-
tients with congenital heart disease.
Why did the authors think that this par-
ticular patient required bosentan treat-
ment based on these measurements? If
we look at the data after treatment and
just before repair, the hemodynamic
does not look much better than with
nitric oxide, as the pulmonary vascular
resistance is 2.6 Wood units or 205
dynes $ s1 $ cm5 and Qp/Qs is 2.24.
Why was the patient considered oper-
able with these values but not before?
If this is based only on mPAP, I would
suggest the authors should discuss the
fact that mLAP also had a significant
decrease.
Finally, if we analyze the measure-
ment 8 months after repair, the pulmo-
nary vascular resistance is 4.2 and the
mean pulmonary arterial pressure is
35 mm Hg—still not normal. We
clearly hope that these values will re-
main at these levels and not rise again
in the coming month, as the outcome,
at least in pediatric patients with recur-
rent pulmonary hypertension after re-
pair, is dismal, as shown recently by
Haworth and colleagues.5
Maurice Beghetti, MD
Cecile Tissot, MD
Pediatric Cardiology Unit
Department of the Child and
Adolescent
Children’s University Hospital of
Geneva
Geneva, Switzerland
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Letters to the EditorMICHAEL E. DEBAKEY
The obituary of Dr DeBakey was
very interesting.1 One of Dr DeBakey’s
pioneering efforts does need special
emphasis. By using autologous saphe-
nous vein(s), on November 23, 1964,2
DeBakey performed the first human
coronary artery bypass graft surgery
to the left anterior descending coronary
artery in an asymptomatic patient after
myocardial infarction.
Shahbudin H. Rahimtoola, MB,
FRCP, DSc (Hon)
LACþUSC Medical Center
Cardiology
Los Angeles, Calif
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